Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
ANI Pharmaceuticals, Inc. - Common Stock
(NQ:
ANIP
)
66.10
+0.79 (+1.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ANI Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Organon Stock Scores Market Leadership With Jump To 83 RS Rating
January 17, 2023
Organon sees its Relative Strength Rating reach the 80-plus level.
Via
Investor's Business Daily
ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP
December 19, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals's Return On Capital Employed Overview
December 12, 2022
Via
Benzinga
ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP
November 28, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 16, 2022
Via
Benzinga
ANI Pharmaceuticals: Q2 Earnings Insights
August 08, 2022
ANI Pharmaceuticals (NASDAQ:ANIP) reported its Q2 earnings results on Monday, August 8, 2022 at 06:50 AM. Here's what investors need to know about the announcement.
Via
Benzinga
ANI Pharmaceuticals: Q1 Earnings Insights
May 10, 2022
ANI Pharmaceuticals (NASDAQ:ANIP) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:50 AM. Here's what investors need to know about the announcement.
Via
Benzinga
ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP
November 16, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues
November 09, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals to Discuss Third Quarter 2022 Financial Results on November 9, 2022, at 8:00 a.m. ET
October 24, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer
September 12, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
September 07, 2022
Upgrades
Via
Benzinga
ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 30, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP
August 29, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 16, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 16, 2022
Via
Benzinga
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP
August 16, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin® Gel
August 08, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP
August 03, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC
July 28, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals to Discuss Second Quarter 2022 Financial Results on August 8, 2022, at 8:00 a.m. ET
July 25, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary
July 18, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP
June 22, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals's Return On Capital Employed Overview
June 08, 2022
According to data from Benzinga Pro, during Q1, ANI Pharmaceuticals's (NASDAQ:ANIP) reported sales totaled $64.48 million. Despite a 16.6% increase in earnings, the company posted a loss of $20.13...
Via
Benzinga
ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition
June 02, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP
June 01, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
May 20, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million
May 10, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals Q1 2022 Earnings Conference Call On May 10, 2022 At 08:30 AM ET
May 06, 2022
ANI Pharmaceuticals (NASDAQ:ANIP) will host a conference call at 08:30 AM ET on May 10, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022
April 19, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.